...
首页> 外文期刊>Clinical Orthopaedics and Related Research >Can a Nomogram Help to Predict the Overall and Cancer-specific Survival of Patients With Chondrosarcoma?
【24h】

Can a Nomogram Help to Predict the Overall and Cancer-specific Survival of Patients With Chondrosarcoma?

机译:罗维图可以帮助预测软骨肉瘤患者的整体和癌症特异性生存期吗?

获取原文
获取原文并翻译 | 示例

摘要

BackgroundMany factors have been reported to be associated with the prognosis of patients with chondrosarcoma, but clinicians have few tools to estimate precisely an individual patient's likelihood of surviving the illness. We therefore sought to develop effective nomograms to better estimate the survival of patients with chondrosarcoma.Questions/purposes(1) Which clinicopathologic features are independent prognostic factors for patients with chondrosarcoma? (2) Can we develop a nomogram to predict 3- and 5-year overall and cancer-specific survival of individual patients with chondrosarcoma based on personalized information?MethodsWe collected information on patients diagnosed with chondrosarcoma between 1988 and 2011 from the Surveillance, Epidemiology, and End Results (SEER) database. The SEER database consists of 18 cancer registries and covers approximately 30% of the total United States population. One thousand thirty-four adult patients with grade II or III chondrosarcoma were included in the cohort (patients with grade I chondrosarcoma were not evaluated in this study), while 327 patients were excluded from the study owing to missing data regarding tumor size or metastasis. Nine hundred nineteen patients (89%) in the cohort had complete followup for at least 1 year. The X-tile program was used to determine optimal cutoff points. Univariate and multivariate analyses were applied to identify independent factors that were further included in the nomograms predicting 3- and 5-year overall survival and cancer-specific survival. Records of 1034 patients were collected and randomly divided into training (n = 517) and validation (n = 517) cohorts. The nomograms were developed based on training cohort. Data for the training cohort were obtained for internal validation of the nomograms, whereas data for the validation cohort were obtained for external validation of the nomograms. Bootstrapped validation, which used a resample with 500 iterations, was applied to validate the nomograms internally and externally.ResultsSix independent prognostic factors for overall survival and six for cancer-specific survival were identified and incorporated to construct nomograms for 3- and 5-year overall and cancer-specific survival. These nomograms can easily be used by providers in the office to estimate a patient's prognosis; the only clinical details a provider needs to use these nomograms effectively are age, histologic subtype, tumor grade, whether surgery was performed, tumor size, and the presence or absence of metastases. Internal and external calibration plots for the probability of 3- and 5-year overall survival and cancer-specific survival showed good agreement between nomogram prediction and observed outcomes. The concordance indices (C-indices) for internal validation of overall survival and cancer-specific survival prediction were 0.803 and 0.829, respectively, whereas the C-indices for external validation were 0.753 and 0.759, respectively.ConclusionsWe were able to develop effective nomograms to predict overall survival and cancer-specific survival for patients with chondrosarcoma; these nomograms require only basic information, which should be available to all providers in the office setting. If these observations can be validated in different registries or databases, the nomograms can assist clinicians in counseling patients regarding therapeutic choices.Level of EvidenceLevel III, prognostic study.
机译:据报道,据据报道,患有软骨肉瘤患者的预后有关的因素,但临床医生很少的工具来估计个体患者幸存疾病的可能性。因此,我们寻求开发有效的载体图,以更好地估计患有Chondrosarcoma患者的存活率.Questons /目的(1)哪种临床病理特征是患有软骨肉瘤患者的独立预后因素? (2)我们可以根据个性化信息预测墨水图,以预测患有软骨肉瘤的个体患者的3和5年的整体和癌症特异性生存吗?方法网络从监测,流行病学,2011年间诊断患有软骨肉瘤的患者的信息,和结束结果(Seer)数据库。 SEER数据库由18名癌症注册机构组成,占美国总人口总数的约30%。群组中包含一千三十四名成年患者,队列中包括II级或III级软骨肉瘤患者(本研究未评估患者患者,而327名患者因缺失关于肿瘤大小或转移的数据而被排除在研究之外。九千九岁患者(89%)在队列中已经完全随访至少1年。 X-Tile程序用于确定最佳截止点。应用单变量和多变量分析来鉴定预测3-和5年整体生存和癌症的存活率中进一步包含的独立因素。收集1034名患者的记录,并随机分为培训(n = 517)和验证(n = 517)群组。载体基于培训队列开发。获得培训队列的数据,用于载体内部验证,而验证队列的数据是为了对载体的外部验证而获得的。使用具有500个迭代的重组的引导验证被应用于验证内部和外部的载体。鉴定,用于整体存活的独立预后因素,六个用于癌症特异性存活率,并纳入整体3年和5年的题图和癌症特异性生存。这些载体可以很容易地由办公室的提供商轻松使用来估计患者的预后;提供者唯一临床细节需要有效地使用这些载体,是年龄,组织学亚型,肿瘤等级,是否进行手术,肿瘤大小,以及转移的存在或不存在。内部和外部校准曲线概率为3-和5年的整体存活和癌症特异性生存率在墨顶预测和观察结果之间表现出良好的一致性。内部存活和癌症特异性生存预测内部验证的一致性指数分别为0.803和0.829,而外部验证的C索引分别为0.753和0.759。结论我们能够开发有效的拓图预测软骨肉瘤患者的整体存活和癌症特异性存活;这些载体图形只需要基本信息,这些信息应该可以在办公室设置中的所有提供商中使用。如果这些观察可以在不同的注册服务或数据库中验证,则载体可以帮助临床医生在咨询患者有关治疗选择的咨询患者。EVIDENCELEVEL III的精神,预后研究。

著录项

  • 来源
  • 作者单位

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

    Fudan Univ Shanghai Canc Ctr Dept Head &

    Neck Surg Shanghai Peoples R China;

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

    Fudan Univ Huashan Hosp Dept Orthopaed 12 Wulumuqizhong Rd Shanghai 200040 Peoples R China;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 骨科学(运动系疾病、矫形外科学) ;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号